Wall Street is positive on Eiger Biopharmaceuticals Inc (EIGR). On average, analysts give EIGR a Strong Buy rating. The average price target is $34.5, which means analysts expect the stock to add by 268.98% over the next twelve months.
That average ranking earns EIGR an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
Investors Observer combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Eiger Biopharmaceuticals Inc Stock Today?
Eiger Biopharmaceuticals Inc (EIGR) stock is higher by 8.44% while the S&P 500 is down -1.09% as of 10:44 AM on Thursday, Oct 15. EIGR has risen $0.73 from the previous closing price of $8.62 on volume of 1,081,960 shares. Over the past year the S&P 500 is up 15.41% while EIGR is down -15.00%. EIGR lost -$2.68 per share the over the last 12 months.